Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.

A 35-year-old transgender woman experienced hair regrowth with feminizing HRT, adding dutasteride and bicalutamide, and plans a hair transplant for further improvement. Estrogen also improved skin appearance, and the user advises against cisgender men using feminizing HRT for hair regrowth.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

The user received trichotest results indicating finasteride is ineffective for them, and they plan to use dutasteride mesotherapy and add cetirizine to minoxidil. They seek advice on incorporating dutasteride into their regimen.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

The conversation is about organizing hair regrowth results using a standard format in a single post for easier access. Treatments mentioned include oral minoxidil, oral finasteride, and dermarolling.

A new brand is seeking 10 U.S.-based individuals aged 25+ experiencing hair loss to test a topical product containing GHK-Cu and Acetyl Tetrapeptide-3. Participants must not be using other treatments like finasteride or minoxidil and will provide feedback and photos.

A user underwent a hair transplant with 3200 grafts and plans to update others on their progress. They previously used minoxidil and finasteride to stabilize hair loss but opted for a transplant for better results.

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

The conversation discusses using cetirizine (Zyrtec) topically to relieve scalp itch associated with hair loss and suggests it may also benefit androgenetic alopecia (AGA). One person found relief from scalp itch after three months on finasteride, noting the itch was linked to areas where hair was lost.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.

Increasing IGF-1 may help hair growth, but it could also increase hair loss in people with high testosterone. Treatments discussed include l-arginine, glutamine, vanadium, Deer Antler Velvet, ATP, Cocarboxylase, l-carnitine, and Mk677.

Switching from finasteride to dutasteride and back to finasteride led to gynecomastia and fatigue, likely due to hormonal imbalances. Suggested treatments include Tamoxifen, Raloxifene, or low-dose Anastrozole, with a recommendation to test testosterone and estradiol levels.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

User ronopibf discusses Fagron TrichoTest, a genetic test for hair loss, and seeks opinions on its effectiveness. Some users support the service, while others call it a scam, with prices ranging from $200-$500.

The user has high DHT levels despite using dutasteride, which may not be effective due to potential damage or spoilage. They are considering a hair transplant if DHT levels don't decrease after two years.

Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.

A trans man is experiencing hair loss due to testosterone therapy but is unwilling to stop the treatment despite concerns about using finasteride. The individual is distressed about balding at a young age but acknowledges it is genetic.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. User feedback suggests 2-deoxy-D-ribose is ineffective.

RU58841 is discussed as a hair loss treatment, with concerns about its effectiveness diminishing after two years due to androgen receptor upregulation. The user is hesitant to start using it, fearing it may worsen their condition over time.

A user with diffuse hair loss after taking accutane, which might have triggered genetic predisposition to AGA; their experience taking finasteride and experiencing side effects of increased oil production, increased sex drive, worsening hair texture; they are considering zinc supplementation with finasteride or other treatments such as alfatradiol or spironolactone.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.